The Risk of New Onset Dementia and/or Alzheimer Disease among Patients with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis

被引:39
|
作者
Motlagh, Reza Sari [1 ]
Quhal, Fahad [1 ]
Mori, Keiichiro [1 ,2 ,3 ]
Miura, Noriyoshi [1 ,4 ]
Aydh, Abdulmajeed [1 ,5 ]
Laukhtina, Ekaterina [1 ,6 ]
Pradere, Benjamin [1 ,7 ]
Karakiewicz, Pierre I. [8 ]
Enikeev, Dmitry V. [6 ]
Deuker, Marina [9 ]
Shariat, Shahrokh F. [1 ,6 ,10 ,11 ,12 ,13 ,14 ,15 ]
机构
[1] Med Univ Vienna, Dept Urol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria
[2] King Fahad Specialist Hosp, Dammam, Saudi Arabia
[3] Jikei Univ, Sch Med, Dept Urol, Tokyo, Japan
[4] Ehime Univ, Grad Sch Med, Dept Urol, Matsuyama, Ehime, Japan
[5] King Faisal Med City, Abha, Saudi Arabia
[6] Sechenov Univ, Inst Urol & Reprod Hlth, Moscow, Russia
[7] Univ Hosp Tours, Dept Urol, Tours, France
[8] Univ Montreal, Ctr Hlth, Canc Prognost & Hlth Outcomes Unit, Montreal, PQ, Canada
[9] Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[10] Weill Cornell Med Coll, Dept Urol, New York, NY USA
[11] Univ Texas Southwestern, Dept Urol, Dallas, TX USA
[12] Karl Landsteiner Inst Urol & Androl, Vienna, Austria
[13] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic
[14] Univ Jordan, Jordan Univ Hosp, Dept Special Surg, Amman, Jordan
[15] European Assoc Urol Res Fdn, Arnhem, Netherlands
来源
JOURNAL OF UROLOGY | 2021年 / 205卷 / 01期
关键词
androgen antagonists; Alzheimer disease; dementia; prostatic neoplasms; COGNITIVE FUNCTION; SEX-HORMONES; MEN;
D O I
10.1097/JU.0000000000001341
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Androgen deprivation therapy is a standard therapy for some patients with localized and almost all patients with metastatic prostate cancer. Although several clinical cohort studies have identified an impact of androgen deprivation therapy on cognitive function, the previous reviews were not able to perform a well designed quantitative synthesis to summarize the risk of dementia and/or Alzheimer disease. Consequently there is still a lack of systematic review and meta-analysis regarding the impact of this risk including more recent studies. Materials and Methods: We conducted a systematic review and meta-analysis of the literature assessing the differential incidence of dementia and/or Alzheimer disease as outcomes in patients with prostate cancer who did vs did not receive androgen deprivation therapy. We queried PubMed (R) and Web of Science (TM) databases from January 1 to 3, 2020. We used random or fixed effects meta-analytic models in the presence or absence of heterogeneity per the I-2 statistic. We performed 6 meta-analyses for all cause dementia, Alzheimer disease and all cause dementia or Alzheimer disease according to the duration of androgen deprivation therapy (up to 12 or more than 12 months). Results: A total of 14 studies were selected after considering inclusion and exclusion criteria. Nine of them reported all cause dementia (ie all types of dementia including Alzheimer disease), with 8 reporting Alzheimer disease. Five studies assessed these outcomes according to the duration of androgen deprivation therapy. The risk of new onset dementia (all cause) and Alzheimer disease was higher in patients with prostate cancer who received androgen deprivation therapy compared to those who did not (HR 1.21, 95% CI 1.11-1.33 and HR 1.16, 95% CI 1.09-1.24). The risk of dementia (all cause) was higher in patients with prostate cancer who received androgen deprivation therapy for more than 12 months (HR 1.36, 95% CI 1.07-1.72); however, for those who had less than 12 months of androgen deprivation therapy exposure the difference was not statistically significant 1.06 (95% CI 0.77-1.28). There was no association between the androgen deprivation therapy duration and the risk of Alzheimer disease (HR 1.21, 95% CI 0.97-1.51 for exposure up to 12 months and HR 1.39, 95% CI 0.69-2.79 for exposure greater than 12 months). Conclusions: Men who receive androgen deprivation therapy for prostate cancer have an increased risk of dementia and/or Alzheimer disease compared to men who do not receive androgen deprivation therapy; this was more pronounced when androgen deprivation therapy was given longer than 12 months.
引用
收藏
页码:60 / 67
页数:8
相关论文
共 50 条
  • [1] Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
    Nead, K. T.
    Sinha, S.
    Nguyen, P. L.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) : 259 - 264
  • [2] Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis
    K T Nead
    S Sinha
    P L Nguyen
    [J]. Prostate Cancer and Prostatic Diseases, 2017, 20 : 259 - 264
  • [3] CARDIOVASCULAR MORTALITY RISK IN PATIENTS WITH PROSTATE CANCER TREATED WITH ANDROGEN DEPRIVATION THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Tan, Neville
    Neil, Christopher
    Cox, Nicholas
    Nolan, Mark
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 248 - 248
  • [4] Androgen Deprivation Therapy and the Risk of Stroke in Patients with Prostate Cancer: An Updated Systematic Review and Meta-Analysis
    Liu, Ranlu
    Zhou, Jiatong
    Xia, Shuai
    Li, Tao
    [J]. UROLOGIA INTERNATIONALIS, 2020, 104 (3-4) : 214 - 221
  • [5] Androgen deprivation therapy in the treatment of prostate cancer and dementia risk: A systematic review and meta-analysis.
    Nead, Kevin Thomas
    Sinha, Sumi
    Nguyen, Paul L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [6] Risk of Fracture During Androgen Deprivation Therapy Among Patients With Prostate Cancer: A Systematic Review and Meta-Analysis of Cohort Studies
    Wu, Cheng Chih
    Chen, Po Yen
    Wang, Shih Wei
    Tsai, Meng Hsuan
    Wang, Yu Chin Lily
    Tai, Ching Ling
    Luo, Hao Lun
    Wang, Hung-Jen
    Chen, Chung Yu
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [7] Is androgen deprivation therapy for prostate cancer associated with cardiovascular disease? A meta-analysis and systematic review
    Liang, Zhen
    Zhu, Jun
    Chen, Longlong
    Xu, Yawei
    Yang, Yongjiao
    Hu, Rui
    Zhang, Wei
    Song, Yuxuan
    Lu, Yi
    Ou, Ningjing
    Liu, Xiaoqiang
    [J]. ANDROLOGY, 2020, 8 (03) : 559 - 574
  • [8] Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
    A Serpa Neto
    M Tobias-Machado
    M A P Esteves
    M D Senra
    M L Wroclawski
    F L A Fonseca
    R B dos Reis
    A C L Pompeo
    A D Giglio
    [J]. Prostate Cancer and Prostatic Diseases, 2012, 15 : 36 - 44
  • [9] Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: A systematic review and meta-analysis
    Wroclawski, M. L.
    Serpa Neto, A.
    Tobias-Machado, M.
    Esteves, M. A.
    Fonseca, F. L.
    Senra, M. D.
    Pompeo, A. C.
    Del Giglio, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis
    Serpa Neto, A.
    Tobias-Machado, M.
    Esteves, M. A. P.
    Senra, M. D.
    Wroclawski, M. L.
    Fonseca, F. L. A.
    dos Reis, R. B.
    Pompeo, A. C. L.
    Giglio, A. D.
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2012, 15 (01) : 36 - 44